Michael Saag, MD
Potential Financial Conflicts of Interest:Consultancies: Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman-LaRoche, OrthoBiotech/Johnson & Johnson, Pfizer/Agouron, Schering-Plough, Shire Pharmaceutical, TherapyEdge, Tibotec/Virco, Trimeris, Virologic; Grants received: Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman-LaRoche, Ortho Biotech/Johnson & Johnson, Pfizer/Agouron, Pharmacia & Upjohn, Triangle Pharmaceuticals.
Requests for Single Reprints: Michael Saag, MD, University of Alabama at Birmingham, CCB Room 178, 908 20th Street South, Birmingham, AL 35294.
Saag M. Is It Time To Proactively Switch Successful Antiretroviral Therapy? Carefully Check Your SWATCH. Ann Intern Med. 2003;139:148–149. doi: 10.7326/0003-4819-139-2-200307150-00014
Download citation file:
© 2018
Published: Ann Intern Med. 2003;139(2):148-149.
DOI: 10.7326/0003-4819-139-2-200307150-00014
HIV, Infectious Disease.
Results provided by: